SCHEMBL19475245

SCHEMBL19475245

COc1ccccc1CNC(=O)c1c(N)sc2c1CCCC2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.68
MAPT P10636 9/20 0.61
ALDH1A1 P00352 8/20 0.61
HPGD P15428 8/20 0.61
KMT2A Q03164 6/20 0.61
MEN1 O00255 5/20 0.61
KDM4E B2RXH2 5/20 0.61
ALOX15 P16050 3/20 0.61
HSD17B10 Q99714 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
THRB P10828 1/20 0.61
TAAR1 Q96RJ0 2/20 0.59
TSHR P16473 2/20 0.58
RCE1 Q9Y256 1/20 0.54
GAA P10253 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
LMNA P02545 2/20 0.51
TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31502665 0.86 GAA (0.59) MAPK1MAPTALDH1A1HPGDKMT2A
SCHEMBL19475101 0.83 ADORA1 (0.60) MAPK1MAPTALDH1A1HPGDKMT2A
SCHEMBL8207916 0.81 TAAR1 (0.78) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL31502646 0.81 MAPT (0.65) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL14829398 0.80 TAAR1 (0.76) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL5460444 0.80 KMT2A (0.78) MAPK1ALDH1A1HPGDKMT2AMEN1
SCHEMBL8199921 0.80 MEN1 (0.57) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL20915168 0.78 MAPT (0.64) MAPK1MAPTALDH1A1HPGDKMT2A
SCHEMBL8206811 0.78 TAAR1 (0.62) MAPK1MAPTALDH1A1HPGDKMT2A
SCHEMBL31502641 0.77 MGAM (0.63) MAPTALDH1A1HPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025042610-A1 PIFITHRIN ANALOGUES AND METHODS OF TREATING RETT SYNDROME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-02-27 WO claimed
WO-2025042610-A1 PIFITHRIN ANALOGUES AND METHODS OF TREATING RETT SYNDROME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-02-27 WO disclosed
US-10647725-B2 Anti-infective 2-aminothiophenes THE UNIVERSITY OF TOLEDO (US) 2020-05-12 US disclosed
US-20190119296-A1 Anti-Infective 2-Aminothiophenes THE UNIVERSITY OF TOLEDO (US) 2019-04-25 US disclosed
WO-2017184947-A1 ANTI-INFECTIVE 2-AMINOTHIOPHENES THE UNIVERSITY OF TOLEDO (US) 2017-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119296-A1 Anti-Infective 2-Aminothiophenes TST, ABAT, TPMT MAPK1 4727/4885MAPT 1615/4885ALDH1A1 2316/4885
US-10647725-B2 Anti-infective 2-aminothiophenes TST, ABAT, TPMT MAPK1 4727/4885MAPT 1615/4885ALDH1A1 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.